These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37094652)

  • 21. A randomized, double-blind, vehicle-controlled crossover study to determine the anti-pruritic efficacy, safety and local dermal tolerability of a topical formulation (srd174 cream) of the long-acting opiod antagonist nalmefene in subjects with atopic dermatitis.
    Herzog JL; Solomon JA; Draelos Z; Fleischer A; Stough D; Wolf DI; Abramovits W; Werschler W; Green E; Duffy M; Rothaul A; Tansley R
    J Drugs Dermatol; 2011 Aug; 10(8):853-60. PubMed ID: 21818506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.
    Wahn U; Bos JD; Goodfield M; Caputo R; Papp K; Manjra A; Dobozy A; Paul C; Molloy S; Hultsch T; Graeber M; Cherill R; de Prost Y;
    Pediatrics; 2002 Jul; 110(1 Pt 1):e2. PubMed ID: 12093983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Steroid-free emollient formulations reduce symptoms of eczema and improve quality of life.
    Weber TM; Babcock MJ; Herndon JH; Schoelermann AM; Filbry AW; Scherdin U; Neufang G; Rippke F
    J Drugs Dermatol; 2014 May; 13(5):589-95. PubMed ID: 24809884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, observer-blind, vehicle-control, multi-center clinical investigation for assessing the efficacy and tolerability of a 1% ectoine and hyaluronic acid 0.1%-containing medical device in pediatric patients with mild-to-moderate atopic dermatitis.
    Alexopoulos A; Dakoutrou M; Nasi L; Thanopoulou I; Kakourou T; Kontara L; Douladiris N; Galani M; Xepapadaki P; Doxani C; Mprotsis T; Zintzaras E; Papadopoulos NG; Kanaka-Gantenbein C; Chrousos GP
    Pediatr Dermatol; 2023 Jan; 40(1):78-83. PubMed ID: 36038984
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of ruxolitinib cream in vitiligo by patient characteristics and affected body areas: Descriptive subgroup analyses from a phase 2, randomized, double-blind trial.
    Hamzavi I; Rosmarin D; Harris JE; Pandya AG; Lebwohl M; Gottlieb AB; Butler K; Kuo FI; Sun K; Grimes P
    J Am Acad Dermatol; 2022 Jun; 86(6):1398-1401. PubMed ID: 34089797
    [No Abstract]   [Full Text] [Related]  

  • 26. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
    Simpson EL; Sinclair R; Forman S; Wollenberg A; Aschoff R; Cork M; Bieber T; Thyssen JP; Yosipovitch G; Flohr C; Magnolo N; Maari C; Feeney C; Biswas P; Tatulych S; Valdez H; Rojo R
    Lancet; 2020 Jul; 396(10246):255-266. PubMed ID: 32711801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized, controlled, double-blind clinical study evaluating the safety and efficacy of MD2011001 cream in mild-to-moderate atopic dermatitis of the face and neck in children, adolescents and adults.
    Patrizi A; Raone B; Neri I; Gurioli C; Carbonara M; Cassano N; Vena GA
    J Dermatolog Treat; 2016 Aug; 27(4):346-50. PubMed ID: 26652026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overview of Safety, Efficacy, and Patient Counseling for Ruxolitinib in Treating Atopic Dermatitis.
    Mancuso-Stewart E; Rodger J; Zirwas M
    Skinmed; 2023; 21(1):40-43. PubMed ID: 36987827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized double-blind controlled trial to compare a triclosan-containing emollient with vehicle for the treatment of atopic dermatitis.
    Tan WP; Suresh S; Tey HL; Chiam LY; Goon AT
    Clin Exp Dermatol; 2010 Jun; 35(4):e109-12. PubMed ID: 19843084
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of a Cream Containing Ceramides and Magnesium in the Treatment of Mild to Moderate Atopic Dermatitis: A Randomized, Double-blind, Emollient- and Hydrocortisone-controlled Trial.
    Koppes SA; Charles F; Lammers L; Frings-Dresen M; Kezic S; Rustemeyer T
    Acta Derm Venereol; 2016 Nov; 96(7):948-953. PubMed ID: 26939522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of an over-the-counter 1% colloidal oatmeal cream in the management of mild to moderate atopic dermatitis in children: a double-blind, randomized, active-controlled study.
    Lisante TA; Nuñez C; Zhang P
    J Dermatolog Treat; 2017 Nov; 28(7):659-667. PubMed ID: 28366039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of Colloidal Oatmeal Topical Atopic Dermatitis Cream on Skin Microbiome and Skin Barrier Properties.
    Capone K; Kirchner F; Klein SL; Tierney NK
    J Drugs Dermatol; 2020 May; 19(5):524-531. PubMed ID: 32484623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Steroid-Free Over-the-Counter Eczema Skin Care Formulations Reduce Risk of Flare, Prolong Time to Flare, and Reduce Eczema Symptoms in Pediatric Subjects With Atopic Dermatitis.
    Weber TM; Samarin F; Babcock MJ; Filbry A; Rippke F
    J Drugs Dermatol; 2015 May; 14(5):478-85. PubMed ID: 25942666
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of pimecrolimus 1% cream in the long term management of atopic hand dermatitis. A double-blind RCT.
    Bauer A; Lange N; Matterne U; Meurer M; Braeutigam M; Diepgen TL
    J Dtsch Dermatol Ges; 2012 Jun; 10(6):426-33. PubMed ID: 22112014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of tolerability and efficacy of a topical emulgel containing nanoliposomal ruxolitinib phosphate in the treatment of mild atopic dermatitis: a before-after single group pilot study.
    Naeimifar A; Ahmad Nasrollahi S; Samadi A; Aryanian Z; Akbari Javar H; Rouini M; Nassiri Kashani M; Firooz A
    J Dermatolog Treat; 2022 Dec; 33(8):3160-3164. PubMed ID: 35943737
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis.
    Ling M; Gottlieb A; Pariser D; Caro I; Stewart D; Scott G; Abrams K
    J Dermatolog Treat; 2005 Aug; 16(3):142-8. PubMed ID: 16096179
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial.
    Gooderham MJ; Forman SB; Bissonnette R; Beebe JS; Zhang W; Banfield C; Zhu L; Papacharalambous J; Vincent MS; Peeva E
    JAMA Dermatol; 2019 Dec; 155(12):1371-1379. PubMed ID: 31577341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emollients for the prevention of atopic dermatitis.
    Kothari A; Locke A; Eiwegger T
    Allergy; 2021 Aug; 76(8):2641-2643. PubMed ID: 33147358
    [No Abstract]   [Full Text] [Related]  

  • 39. Ruxolitinib Cream Has Dual Efficacy on Pruritus and Inflammation in Experimental Dermatitis.
    Scuron MD; Fay BL; Connell AJ; Peel MT; Smith PA
    Front Immunol; 2020; 11():620098. PubMed ID: 33658996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized half-body, double blind, controlled trial on the effects of a pH-modified moisturizer vs. standard moisturizer in mild to moderate atopic dermatitis.
    Goh SW; Jamil A; Safian N; Md Nor N; Muhammad N; Saharudin NL
    An Bras Dermatol; 2020; 95(3):320-325. PubMed ID: 32291095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.